Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease
Article first published online: 17 MAR 2005
Alimentary Pharmacology & Therapeutics
Volume 21, Issue 6, pages 733–738, March 2005
How to Cite
Mahadevan, U., Kane, S., Sandborn, W. J., Cohen, R. D., Hanson, K., Terdiman, J. P. and Binion, D. G. (2005), Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Alimentary Pharmacology & Therapeutics, 21: 733–738. doi: 10.1111/j.1365-2036.2005.02405.x
- Issue published online: 17 MAR 2005
- Article first published online: 17 MAR 2005
- Accepted for publication 17 January 2005
Aim: To study the effects of infliximab on pregnancy and foetal outcome.
Methods: We conducted a retrospective chart review of women with Crohn's disease treated intentionally with infliximab during pregnancy. The primary outcome measure was the occurrence of congenital malformations. Secondary outcome measures were the rate of premature birth, low-birth weight, small for gestational age infants, intrauterine growth retardation and caesarean section.
Results: Ten women were identified. Eight women received maintenance infliximab infusions throughout their pregnancy and two women received their initial infliximab infusions during pregnancy. All 10 pregnancies ended in live births. No infants had congenital malformations, intrauterine growth retardation or small for gestational age parameters. Three infants were premature and one had low-birth weight. Eight women had a caesarean section.
Conclusions: This is the first reported series of intentional infliximab use throughout pregnancy. These data, combined with other studies of inadvertent use of infliximab during pregnancy, suggest that the benefits of infliximab in achieving response and maintaining remission in mothers with Crohn's disease may outweigh the risk to the foetus of exposure to the drug. Further prospective data collection will be helpful to confirm these findings.